Björklund Pharma

Advancing healthcare and wellness

  • Home
  • Company
  • Pipeline
  • Publications
  • Media
  • Contact

Sleep

Product Candidate

SomnBon

Quality sleep is essential for overall well-being, yet many individuals struggle to achieve restful sleep due to various factors such as stress, lifestyle changes, and environmental influences. To address this common issue, Björklund Pharma has developed SomnBon, an herbal supplement that promotes restful sleep and enhances sleep quality naturally.

SomnBon combines three herbal extracts known for their calming and sleep-enhancing properties. Valerian root (Valeriana officinalis) (450 mg), a time-honored remedy in traditional medicine, soothes the body and mind, reducing restlessness and creating a tranquil state conducive to restful sleep. Lemon balm (Melissa officinalis; 300 mg) is renowned for its ability to soothe the nervous system and alleviate anxiety and stress to prepare the mind for a peaceful sleep experience. Passionflower (Passiflora incarnata; 500 mg) supports deep and satisfying sleep, promoting relaxation, easing tension, and improving overall sleep quality.

Research supports the potential benefits of SomnBon’s active ingredients in promoting restful sleep. Clinical trials have shown promising results, including reduced sleep latency, increased sleep duration, and improved sleep quality. SomnBon has a favorable safety profile with minimal side effects and no potential risks associated with dependency or adverse reactions.

For adults seeking to improve their sleep quality, taking one tablet of SomnBon orally with water approximately 30 minutes before bedtime is recommended. Adherence to the recommended dosage is important, and it is advisable to consult a healthcare professional if there are underlying medical conditions or concurrent medication usage.

While SomnBon is generally well-tolerated, it is important to note that rare side effects may include mild gastrointestinal discomfort, allergic reactions, daytime drowsiness, potential medication interactions, and individual sensitivity. Monitoring for any unexpected or severe side effects is recommended, and healthcare professional guidance should be sought if necessary.

Company News

  • New COVID-19 Research Provides Insights on the Crucial Role of Zinc in Protein Targets of Drugs That Block SARS-CoV-2 Infection
  • A Possible New Medicine for Multiple Sclerosis?
  • Thymosin Beta 4 in Dry Eye Syndrome
  • The Role of Thymosin Beta 4 in COVID-19 Treatment

Company News

  • New COVID-19 Research Provides Insights on the Crucial Role of Zinc in Protein Targets of Drugs That Block SARS-CoV-2 Infection
  • A Possible New Medicine for Multiple Sclerosis?
  • Thymosin Beta 4 in Dry Eye Syndrome
  • The Role of Thymosin Beta 4 in COVID-19 Treatment

Contact Us

Björklund Pharma AS
Toften 24
8610 Mo i Rana
Norway

Phone: +47 411 11 942
Email: info(at)bjorklundpharma.com

Copyright © 2025 Björklund Pharma AS